<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1317">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01691300</url>
  </required_header>
  <id_info>
    <org_study_id>99-2177A</org_study_id>
    <nct_id>NCT01691300</nct_id>
  </id_info>
  <brief_title>C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT</brief_title>
  <acronym>ACTMM</acronym>
  <official_title>C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT
      PET/CT) may help detect lesions before treatment and evaluate response following therapy in
      patients with from multiple myeloma (MM). This study aimed to prospectively assess the
      clinical utility of ACT PET/CT in MM as compared to the commonly used
      F18-fluorodeoxyglucose(FDG).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Pretreatment lesion detection</measure>
    <time_frame>Within 2 weeks before initiation of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-induction response assessment</measure>
    <time_frame>Approximately 4 months after initiation of therapy depending on the regimen</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-ASCT response assessment</measure>
    <time_frame>Approximately 3 months after ASCT</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>With 2 years of follow-up time</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on clinical follow-up (M-protein or FLC assay, bone marrow examination or imaging findings)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ACT PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ACT PET/CT</intervention_name>
    <description>Old tracer but new indication</description>
    <arm_group_label>ACT PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 20 years of age

          -  previously untreated

          -  complete pre-treatment clinical staging including bone marrow examination

          -  written informed consent to participate in the study

        Exclusion Criteria:

          -  concurrent active malignant tumor(s)

          -  pregnant or breast feeding women

          -  non-compliant to PET/CT or to MRI

          -  marked renal impairment (contraindicated for contrast-enhanced MRI)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chieh Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Imaging Center and Nuclear Medicine, Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hostpial</name>
      <address>
        <city>Gueishan</city>
        <state>Taoyuan county</state>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh Lin, MD, PhD</last_name>
      <phone>+886 3 3281200</phone>
      <phone_ext>3594</phone_ext>
      <email>sophieclin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chieh Lin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 27, 2012</lastchanged_date>
  <firstreceived_date>September 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C11-acetate PET/CT</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Pretreatment staging</keyword>
  <keyword>Response assessment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
